BioCentury’s roundup of translational innovations

BioCentury’s roundup of translational news

High risk-high reward replaced with well-defined activity in focused indications

Host targets, cross-reactive mAbs and COVID-19 countermeasures stand out in BioCentury’s Distillery

Debiopharm will bank €188 million ($226.6 million) for pipeline development now that the biotech has partnered lead program xevinapant with Merck KGaA, adding the German biopharma’s

As the technology goes mainstream, next-gen molecules will use new enzymes, tap new pathways, and address PK/PD challenges

Amgen’s Nuevolution acquisition is powering its push into targeted protein degradation and the wider world of induced proximity therapies

How Cullgen is expanding the repertoire of E3 ligases used in protein degradation